Regeneron CAPELLA

Status: Closed

ClinicalTrials.gov Identifier: NCT02418754

Regeneron CAPELLA R2176-3AMD-1417: A Phase 2, Double-masked, Randomized, Controlled, Multiple-dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-related Macular Degeneration

Condition: Neovascular AMD

Study Type: Interventional

Duration: 52 weeks

Eligibility:

  • Ages: 50 years and older
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.